On Tuesday, Xeris Biopharma Holdings Inc (NASDAQ: XERS) opened higher 4.37% from the last session, before settling in for the closing price of $3.20. Price fluctuations for XERS have ranged from $1.69 to $3.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 241.10%. Company’s average yearly earnings per share was noted 21.65% at the time writing. With a float of $138.51 million, this company’s outstanding shares have now reached $149.00 million.
Let’s determine the extent of company efficiency that accounts for 377 employees. In terms of profitability, gross margin is 77.02%, operating margin of -24.11%, and the pretax margin is -35.02%.
Xeris Biopharma Holdings Inc (XERS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xeris Biopharma Holdings Inc is 7.09%, while institutional ownership is 43.75%. The most recent insider transaction that took place on Aug 12 ’24, was worth 10,147. In this transaction Director of this company bought 4,515 shares at a rate of $2.25, taking the stock ownership to the 25,200 shares. Before that another transaction happened on Aug 09 ’24, when Company’s Director bought 4,285 for $2.37, making the entire transaction worth $10,134. This insider now owns 20,685 shares in total.
Xeris Biopharma Holdings Inc (XERS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.65% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Check out the current performance indicators for Xeris Biopharma Holdings Inc (XERS). In the past quarter, the stock posted a quick ratio of 1.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.18 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Looking closely at Xeris Biopharma Holdings Inc (NASDAQ: XERS), its last 5-days average volume was 1.13 million, which is a drop from its year-to-date volume of 1.49 million. As of the previous 9 days, the stock’s Stochastic %D was 22.20%. Additionally, its Average True Range was 0.17.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 61.87%, which indicates a significant increase from 37.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.27% in the past 14 days, which was lower than the 44.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.33, while its 200-day Moving Average is $2.66. However, in the short run, Xeris Biopharma Holdings Inc’s stock first resistance to watch stands at $3.40. Second resistance stands at $3.45. The third major resistance level sits at $3.55. If the price goes on to break the first support level at $3.25, it is likely to go to the next support level at $3.15. Should the price break the second support level, the third support level stands at $3.10.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
There are currently 149,081K shares outstanding in the company with a market cap of 497.93 million. Presently, the company’s annual sales total 163,910 K according to its annual income of -62,260 K. Last quarter, the company’s sales amounted to 54,270 K and its income totaled -15,740 K.
